Zusammenfassung
Bereits bei den frühen klinischen Studien zur Behandlung metastasierter kolorektaler Karzinome mit 5-Fluorouracil (5-FU)/Folinsäure ebenso wie später mit Irinotecan zeigte sich, dass chemotherapieinduzierte Diarrhöen (CID) als mögliche schwerwiegende Nebenwirkung einer antitumoralen Therapie berücksichtigt werden müssen. Intestinale Funktionsstörungen wie Durchfälle und Obstipation stellen dabei nicht nur eine zusätzliche physische und emotionale Belastung für den Patienten und seine Angehörigen dar, sondern führen auch zu eventuell notwendigen Dosisanpassungen und Therapieunterbrechungen mit verminderter Effektivität der Behandlung. Vor allem bei der Behandlung kolorektaler Tumoren gilt die CID neben Leukopenie, Granulozytopenie und Thrombozytopenie als eine der häufigsten dosislimitierenden und in einigen Fällen auch lebensgefährlichen Nebenwirkungen der Therapie. Das rechtzeitige Erkennen der Situation und Behandeln der Symptome können die hohe Mortalität und Morbidität, die mit CID verbunden ist, verringern. Die Beurteilung des Schweregrades der Nebenwirkungen richtet sich gewöhnlich nach dem „National Cancer Institute Common Toxicity Criteria for Grading the Severity of Diarrhea”. In dieser Übersicht soll auf das heutige Management der CID eingegangen werden, da für Patienten, die auf eine konventionelle pharmakologische Therapie nicht ansprechen, spezifische, ursachenorientierte Therapeutika zur Verfügung stehen.
Abstract
Chemotherapy-induced diarrhea (CID) became first apparent during clinical studies on the combination of 5-FU with leucovorin and, furthermore, with irinotecan in the treatment of metastatic colorectal carcinoma. Bowel dysfunctions, such as diarrhea and constipation, can be a disturbing side effect in chemotherapy that may result not only in significant physical and emotional distress for the patients and care givers, but also in diminished therapeutic efficacy due to dose limitations and treatment interruptions. Besides leucocytopenia, granulocytopenia and thrombocytopenia, CID is considered one of the main dose-limiting toxicities associated with chemotherapy agents, especially in treatment regimens for colorectal cancer and can even be life-threatening. Early recognition and treatment can prevent the morbidity and mortality associated with CID. The most commonly used assessment tool is the National Cancer Institute Common Toxicity Criteria for Grading the Severity of Diarrhea. In this review, we will concentrate on the modern management of CID. Traditional pharmacological management of CID has included mainly non-specific agents. For patients who are refractory to non-specific therapy, there are more sophisticated, specific therapeutic agents available.
Schlüsselwörter
Diarrhö - Chemotherapie - Irinotecan - CPT-11 - 5-Fluorouracil - Octreotid - Loperamid - Glutamin
Key words
Diarrhea - chemotherapy - irinotecan - CPT-11 - 5-fluorouracil - octreotide - loperamide - glutamine
Literatur
-
1
de Forni M, Bugat R, Chabot G G. et al .
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
Cancer Res.
1994;
54
4347-4354
-
2
Petrelli N, Douglass H O Jr, Herrera L. et al .
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
J Clin Oncol.
1989;
7
1419-1426
-
3
Engelking C, Wickham R, Iwamoto R.
Cancer-related gastrointestinal symptoms: Dilemmas in assessment and management.
Dev Support Cancer Care.
1996;
1
3-10
-
4
Hryniuk W, Figueredo A, Goodyear M.
Application of dose intensity to problems in chemotherapy of breast and colorectal cancer.
Semin Oncol.
1987;
14 (Suppl)
3-11
-
5
Hryniuk W, Bush H.
The importance of dose intensity in chemotherapy of metastatic breast cancer.
J Clin Oncol.
1984;
2
1281-1288
-
6
Norton L.
Evolving concepts in the systemic drug therapy of of breast cancer.
Semin Oncol.
1997;
24 (Suppl)
S10--3 - S10-10
-
7 Regnard C FB, Tempest S. A guide to symptom relief in advanced cancer. Manchester; Haigh and Hockland 1992
-
8 Sykes N P. Constipation and diarrhea. Doyle D, Hanks GW, MacDonald N Oxford textbook of palliative medicine Oxford; Oxford Medical 1998: 299-310
-
9
Levy M H.
Constipation and diarrhea in cancer patients.
Cancer Bull.
1991;
43
412-422
-
10
Arbuckle R B, Huber S L, Zacker C.
The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study.
Oncologist.
2000;
5
250-259
-
11
Leichman C G, Fleming T R, Muggia F M. et al .
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
J Clin Oncol.
1995;
13
1303-1311
-
12
International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: .
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.
Lancet.
1995;
345
939-944
-
13
Laufman L R, Bukowski R M, Collier M A. et al .
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.
J Clin Oncol.
1993;
11
1888-1893
-
14
Macdonald J S.
Adjuvant therapy for colon cancer.
CA Cancer J Clin.
1997;
47
243-256
-
15
Wadler S, Benson A B III, Engelking C. et al .
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
J Clin Oncol.
1998;
16
3169-3178
-
16
Mercadante S.
Diarrhea in terminally ill patients: pathophysiology and treatment.
J Pain Symptom Manage.
1995;
10
298-309
-
17
Fernandez-Banares F, Villa S, Esteve M. et al .
Acute effects of abdominopelvic irradiation on the orocecal transit time: its relation to clinical symptoms, and bile salt and lactose malabsorption.
Am J Gastroenterol.
1991;
86
1771-1777
-
18
Erickson B A, Otterson M F, Moulder J E. et al .
Altered motility causes the early gastrointestinal toxicity of irradiation.
Int J Radiat Oncol Biol Phys.
1994;
28
905-912
-
19
Sher M E, Bauer J.
Radiation-induced enteropathy.
Am J Gastroenterol.
1990;
85
121-128
-
20
Baskerville A, Batter-Hatton D.
Intestinal lesions induced experimentally by methotrexate.
Br J Exp Pathol.
1977;
58
663-669
-
21
de Roy v an Zuidewijn DB, Schillings P H. et al .
Morphometric analysis of the effects of antineoplastic drugs on mucosa of normal ileum and ileal anastomoses in rats.
Exp Mol Pathol.
1992;
56
96-107
-
22
Milles S S, Muggia A L, Spiro H M.
Colonic histologic changes induced by 5-fluorouracil.
Gastroenterology.
1962;
43
391-399
-
23
Advanced colorectal cancer meta-analysis project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate.
J Clin Oncol.
1992;
10
896-903
-
24
Kohne C H, Wils A, Lorenz M. et al .
Randomized phase III study of high-dose fluorouracil given as weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of research and treatment of cancer gastrointestinal group study 40 952.
J Clin Oncol.
2003;
21
3721-3228
-
25
Poon M A, O’Connell M J, Wieand H S. et al .
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.
J Clin Oncol.
1991;
9
1967-1972
-
26
Madisch A, Wiedbrauck F, Marquard F. et al .
5-Fluorouracil-induced colitis - a review based upon consideration of 6 cases.
Z Gastroenterol.
2002;
40
59-66
-
27
Daniele B, Secondulfo M, De Vivo R. et al .
Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer.
J Clin Gastroenterol.
2001;
32
228-230
-
28
Tuchman M, Stoeckeler J S, Kiang D T. et al .
Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity.
N Engl J Med.
1985;
313
245-249
-
29
Harris B E, Song R, Soong S J. et al .
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion.
Cancer Res.
1990;
50
197-201
-
30
Van Kuilenburg A B, Vreken P, Abeling N G. et al .
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency.
Hum Genet.
1999;
104
1-9
-
31
Allegra C J.
Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?.
Clin Cancer Res.
1999;
5
1947-1949
-
32
Di Paolo A, Danesi R, Falcone A. et al .
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Ann Oncol.
2001;
12
1301-1306
-
33
Stephan F, Etienne M C, Wallays C. et al .
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
Am J Med.
1995;
99
685-688
-
34
Takimoto C H, Lu Z H, Zhang R. et al .
Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
Clin Cancer Res.
1996;
2
477-481
-
35
Milano G, Etienne M C.
Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
Ther Drug Monit.
1996;
18
335-340
-
36
Fukuoka M, Niitani H, Suzuki A. et al .
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
J Clin Oncol.
1992;
10
16-20
-
37
Shimada Y, Yoshino M, Wakui A. et al .
Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.
J Clin Oncol.
1993;
11
909-913
-
38
Abigerges D, Armand J P, Chabot G G. et al .
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
J Natl Cancer Inst.
1994;
86
446-449
-
39
Dodds H, Rivory L P.
The mechanisms for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
Mol Pharmacol.
1999;
56
1346-1353
-
40
Blandizzi C, Danesi R, De Paolis B. et al .
Cholinergic toxic syndrome by the anticaner drug irinotecan: Acetylcholinesterase does not play a major role.
Clin Pharmacol Ther.
2002;
71
263-271
-
41
Blandizzi C, De Paolis B, Colucci R. et al .
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.
Br J Pharmacol.
2001;
132
73-84
-
42
Kawato Y, Sekiguchi M, Akahane K. et al .
Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.
J Pharm Pharmacol.
1993;
45
444-448
-
43
Takasuna K, Kasai Y, Kitano Y. et al .
Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Nippon Yakurigaku Zasshi.
1995;
105
447-460
-
44
Kaneda N, Nagata H, Furuta T. et al .
Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
Cancer Res.
1990;
50
1715-1720
-
45
Kawato Y, Aonuma M, Hirota Y. et al .
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Cancer Res.
1991;
51
4187-4191
-
46
Charman W N, Porter C J, Mithani S. et al .
Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.
J Pharm Sci.
1997;
86
269-282
-
47
Bugaut M.
Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals.
Comp Biochem Physiol B.
1987;
86
439-472
-
48
Kobayashi K, Bouscarel B, Matsuzaki Y. et al .
pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Int J Cancer.
1999;
83
491-496
-
49
Atsumi R, Okazaki O, Hakusui H.
Pharmacokinetics of SN-38 [(+)-(4S)- 4,11-diethyl-4,9-dihydroxy-1H-pyrano[3’,4’:6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
Biol Pharm Bull.
1995;
18
1114-1119
-
50
Araki E, Ishikawa M, Iigo M. et al .
Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
Jpn J Cancer Res.
1993;
84
697-702
-
51
Kobayashi K, Shinbara A, Kamimura M. et al .
Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
Cancer Chemother Pharmacol.
1998;
42
53-58
-
52
Takeda Y, Kobayashi K, Akiyama Y. et al .
Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Int J Cancer.
2001;
92
269-275
-
53
Takasuna K, Hagiwara T, Hirohashi M. et al .
Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
Cancer Res.
1996;
56
3752-3757
-
54
Iyer L, King C D, Whitington P F. et al .
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
J Clin Invest.
1998;
101
847-854
-
55
Atsumi R, Suzuki W, Hakusui H.
Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.
Xenobiotica London.
1991;
21
1159-1169
-
56
Kehrer D F, Sparreboom A, Verweij J. et al .
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Clin Cancer Res.
2001;
7
1136-1141
-
57
Wasserman E, Myara A, Lokiec F. et al .
Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports.
Ann Oncol.
1997;
8
1049-1051
-
58
Gupta E, Lestingi T M, Mick R. et al .
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Cancer Res.
1994;
54
3723-3725
-
59
Taminiau J A, Gall D G, Hamilton J R.
Response of the rat small-intestine epithelium to methotrexate.
Gut.
1980;
21
486-492
-
60
Benson A B III, Goldberg R M.
Optimal use of the combination of irinotecan and 5-Fluorouacil.
Sem Oncol.
2003;
30
68-77
-
61
Saltz L B, Cox J V, Blanke C D. et al .
Iriontecan plus fluorouracil and leukovorin for metastatic colorectal cancer.
N Engl J Med.
2000;
343
905-914
-
62
Douillard J Y, Cunningham D, Roth A D. et al .
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet.
2000;
355
1041-1047
-
63 National Cancer Institute Common Toxicity Criteria for Grading the Severity of Diarrhea .National Cancer Institute: Investigator’s Handbook: A manual for participants in clinical trials of investigational agents sponsored by DCTD, NCI. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute Bethesda, MD; National Cancer Institute 1993
-
64
Mathijssen R H, Verweij J, de Bruijn P. et al .
Effect of St. John’s wort on irinotecan metabolism.
J Natl Cancer Inst.
2002;
94
1247-1249
-
65
O’Malley M E, Wilson S R.
US of gastrointestinal tract abnormalities with CT correlation.
Radiographics.
2003;
23
59-72
-
66
Du P ont HL.
Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology.
Am J Gastroenterol.
1997;
92
1962-1975
-
67
Bavaro M F.
Neutropenic enterocolitis.
Curr Gastroenterol Rep.
2002;
4
297-301
-
68
Kouroussis C, Samonis G, Androulakis N.
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Am J Clin Oncol.
2000;
23
309-313
-
69 Martz C H. Diarrhea. Groenwald SL, Frogge MH, Goodmann M et al Cancer Symptom Management Boston, MA; Jones & Barlett 1996: 498-520
-
70
Hogan C M.
The nurse’s role in diarrhea management.
Oncol Nurs Forum.
1998;
25
879-886
-
71
Schiller L R.
Review article: anti-diarrheal pharmacology and therapeutics.
Aliment Pharmacol Ther.
1995;
9
87-106
-
72
Olm M, Gonzales F J, Garcia-Valdecasas J C. et al .
Necrotising colitis with perforation in diarrhoic patients treated with loperamide.
Eur J Clin Pharmacol.
1991;
40
415-416
-
73
Ericsson C D, Johnson P C.
Safety and efficacy of loperamide.
Am J Med.
1990;
88
10S-14S
-
74
Catimel G, Chabot G G, Guastalla J P. et al .
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Ann Oncol.
1995;
6
133-140
-
75
Abigerges D, Chabot G G, Armand J P. et al .
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
J Clin Oncol.
1995;
13
210-221
-
76
Merrouche Y, Extra J M, Abigerges D. et al .
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
J Clin Oncol.
1997;
15
1080-1086
-
77
Gandia D, Abigerges D, Armand J P. et al .
CPT-11-induced cholinergic effects in cancer patients.
J Clin Oncol.
1993;
11
196-197
-
78
Cooper J C, Williams N S, King R F. et al .
Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea.
Br J Surg.
1986;
73
128-131
-
79
Dueno M I, Bai J C, Santangelo W C. et al .
Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel.
Dig Dis Sci.
1987;
32
1092-1096
-
80
Fried M.
Octreotide in the treatment of refractory diarrhea.
Digestion.
1999;
60 (Suppl 2)
42-46
-
81
Cascinu S, Fedeli A, Fedeli S L. et al .
Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin.
Oncology.
1994;
51
70-73
-
82
Cascinu S, Fedeli A, Fedeli S L. et al .
Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
J Clin Oncol.
1993;
11
148-151
-
83
Cascinu S, Fedeli A, Fedeli S L. et al .
Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.
Eur J Cancer.
1992;
28
482-483
-
84
Barbounis V, Koumakis G, Vassilomanolakis M. et al .
Control of irinotecan-induced diarrhea by octreotide after loperamide failure.
Supp Care Cancer.
2001;
9
258-260
-
85
Meropol N J, Blumenson L E, Creaven P J.
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
Am J Clin Oncol.
1998;
21
135-138
-
86
van der Hulst R R, van Kreel B K, von Meyenfeldt M F. et al .
Glutamine and the preservation of gut integrity.
Lancet.
1993;
341
1363-1365
-
87
Tremel H, Kienle B, Weilemann L S. et al .
Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal function in the critically ill.
Gastroenterology.
1994;
107
1595-1601
-
88
Fox A D, Kripke S A, De Paula J. et al .
Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis.
JPEN J Parenter Enteral Nutr.
1988;
12
325-331
-
89
Rombeau J L.
A review of the effects of glutamine-enriched diets on experimentally induced enterocolitis.
JPEN J Parenter Enteral Nutr.
1990;
14 (4 Suppl)
100S-105S
-
90
Decker-Baumann C, Buhl K, Frohmuller S. et al .
Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer.
Eur J Cancer.
1999;
35
202-207
-
91
Savarese D, Al-Zoubi A, Boucher J.
Glutamine for irinotecan diarrhea.
J Clin Oncol.
2000;
18
450
-
92
Savarese D MF, Savy G, Vahdat L. et al .
Prevention of chemotherapy and radiation toxicity with glutamine.
Cancer Treat Rev.
2003;
29
501-513
-
93
Ikegami T, Ha L, Arimori K. et al .
Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Cancer Res.
2002;
62
179-187
-
94
Takeda Y, Kobayashi K, Akiyama Y. et al .
Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.
Int J Cancer.
2001;
92
269-275
-
95
Meierhofer C, Dunzendorfer S, Wiedermann C J.
Theoretical basis for the activity of thalidomide.
BioDrugs.
2001;
15
681-703
-
96
Ehrenpreis E D, Kane S V, Cohen L B. et al .
Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial.
Gastroenterology.
1999;
117
1271-1277
-
97
Govindarajan R, Heaton K M, Broadwater R. et al .
Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Lancet.
2000;
356
566-567
-
98
Lenfers B H, Loeffler T M, Droege C M. et al .
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Ann Oncol.
1999;
10
1251-1253
-
99
Wolf H.
Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
Scand J Rheumatol Suppl.
2000;
113
37-45
-
100
Bailey L D Jr, Stewart W R Jr, McCallum R W.
New directions in the irritable bowel syndrome.
Gastroenterol Clin North Am.
1991;
20
335-349
-
101
Steadman C J, Talley N J, Phillips S F. et al .
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
Mayo Clin Proc.
1992;
67
732-738
-
102
Nightingale J M, Walker E R, Burnham W R. et al .
Short bowel syndrome.
Digestion.
1990;
45 (Suppl 1)
77-83
-
103
Mennie A T, Dalley V M, Dinneen L C. et al .
Treatment of radiation-induced gastrointestinal distress with acetylsalicylate.
Lancet.
1975;
2
942-943
-
104
Simon D M, Cello J P, Valenzuela J. et al .
Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea.
Gastroenterology.
1995;
108
1753-1760
-
105
Weh H J, Zschaber R, Braumann D. et al .
A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA in untreated patients with metastatic colorectal carcinoma.
Onkologie.
1998;
21
403-407
-
106
Porschen R, Bermann A, Loffler T. et al .
Fluorouracil plus leukocorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01.
J Clin Oncol.
2001;
19
1787-1794
-
107
Douillard J Y, Cunningham D, Roth A D. et al .
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet.
2000;
355
1041-1047
-
108
Koehne C H, van Cutsem E, Wils A.
Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of the EORTC GI Group Study 40 986.
Proc Am Soc Clin Oncol.
2003;
21
A1018
-
109
De Gramont A, Figer A, Seymour M. et al .
Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
J Clin Oncol.
2000;
18
2938-2947
PD Dr. Frank Kullmann
Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg
Franz-Josef-Strauß-Allee 11
93042 Regensburg
Email: frank.kullmann@klinik.uni-regensburg.de
